Current Editions
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
Finance
Regulation
Defending accelerated approval. Plus: endpoint innovation & AIM amiss: a BioCentury podcast
Why it’s wrong to conclude half of cancer accelerated approvals are useless
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
Management Tracks
Bill Meury named CEO of Anthos
Plus: Fujimoto to lead Takeda-Astellas-Sumitomo’s JV, and updates from Sofinnova Partners, SystImmune, Amarna and Cytonus
BioCentury ISSN 1097-7201